[Comparison of captopril and lisinopril in the treatment of mild and moderate hypertension].
The antihypertensive efficacy and safety of lisinopril (L), a novel ACE inhibitor, was compared to captopril (C), the known and already approved drug in our country in a multicenter double-blind Yugoslav trial. The study included 91 mild-to-moderate hypertensive patients of both sexes. Forty-six patients were randomized to receive captopril and 45 lisinopril. After a 2 week placebo, the examinees were administered either L in increasing dose of 10, 20, or 40 mg per day (amount necessary to achieve normotension), or C in a dosage of 25, 50, or 100 mg per day. During the 8 week formal trial L decreased the systolic blood pressure by an average of 14.9% from the initial values, and the diastolic pressure by some 15.2%. The same parameters were lowered on C by 11.2%, and 11.7%, respectively. Although the L effects were more pronounced, the observed differences did not reach the level of statistical significance (except for the dose-to-normotension relationship which was significantly better in the L group). It is concluded that both ACEIs under study showed comparable efficacy and tolerability, L being marginally more potent, and longer acting.